Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
We studied the effect of intravenous infusion of synthetic truncated GLP-1 (proglucagon 78-107-amide) on fasting and postprandial gastric acid secretion, gastric emptying, and pancreatic secretion of trypsin and lipase in eight normal volunteers using marker dilution and aspiration technique. The infusion resulted in a plasma concentration of 110 +/- 14 pmol/liter (mean +/- SEM). Truncated GLP-1 significantly inhibited postprandial acid secretion by 43 +/- 11% in spite of unchanged plasma gastrin concentration. Gastric emptying rate decreased significantly; 50% emptying time increased from 16 +/- 2 min to 30 +/- 5 min. Postprandial trypsin and lipase outputs were significantly inhibited by 47 +/- 17% and 40 +/- 9% during truncated GLP-1 infusion. Pancreatic enzyme output was linearly correlated to gastric emptying, and truncated GLP-1 did not affect this relationship, suggesting that the effect on pancreatic secretion was secondary to the effect on gastric emptying. Postprandial insulin and glucagon concentrations were similar with and without truncated GLP-1 infusion in spite of significantly lower blood glucose levels (5.2 +/- 0.2 versus 3.7 +/- 0.3), indicating that GLP-1 stimulated insulin secretion and inhibited glucagon secretion. In conclusion, our results suggest that truncated GLP-1 act as a physiological inhibitor of gastric and pancreatic functions in man.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, GLP-1R agonism not only emerged as a powerful tool in the treatment of T2D and excess adiposity56, but also displayed favorable effects on the cardiovascular system57 and neurodegenerative diseases55.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [57]
In the citing paper
“GLP-1 has been shown to inhibit glucagon secretion and slow gastric emptying.5, 6”
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Physiology of the Gastrointestinal Tract
Ouyang, A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410100162049 · Cited by 950
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Albano, J. D. M., Ekins, R. P., Maritz, G., & Turner, R. C. (1972) · Acta Endocrinologica · doi:10.1530/acta.0.0700487 · Cited by 620
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Self-citationØRSKOV, C., HOLST, J. J., KNUHTSEN, S., BALDISSERA, F. G. A., POULSEN, S. S., & NIELSEN, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 482
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citation
Research works printed but not linked: 4
- Holst JJ: Enteroglucagon. Adv Metab Dis 11:392?419, 1988
- Dimagno EP: Alternations and consequences of interdigestive and poststimulatory human exocrine pancreatic secretion in health and disease. Scand J Gastroenterol 12(suppl 87): 69, 1983
- Holst JJ, Creutzfeldt M, Holm G, Jensen E, Poulsen D, Sparsø B, Schmidt A: Persistent glucagonemia after pancreatectomy in pigs. Diabete Metab 4:75?79, 1978
- Solomon TE: Control of exocrine pancreatic secretion.In Physiology of the Gastrointestinal Tract, 2nd ed. LR Johnson (ed). New York, Raven Press, 1987, pp 1173?1208
Cited by
Items 101–200 of 687
Inhibition of Sham Feeding-Stimulated Human Gastric Acid Secretion by Glucagon-Like Peptide-2
Wøjdemann, M., Wettergren, A., Hartmann, B., Hilsted, L., & Holst, J. J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5840 · Cited by 167
Self-citationEdholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164
Self-citationDeterminants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7743 · Cited by 164
Self-citationShimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., & Kaku, K. (2011) · Diabetologia · doi:10.1007/s00125-011-2069-9 · Cited by 161
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1
Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K., & Young, A. (2001) · Drug Development Research · doi:10.1002/ddr.1195 · Cited by 158
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“Acute IV administration of GLP-1 slows gastric emptying profoundly and dose-dependently (12), accompanied by relaxation of the gastric fundus, increased gastric compliance, inhibition of antral contractility, and increased pyloric tone (13, 14).”
Frank, J. W., Saslow, S. B., Camilleri, M., Thomforde, G. M., Dinneen, S. F., & Rizza, R. A. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90382-8 · Cited by 157
de Fonseca, F. R., Navarro, M. A., Álvarez, E., Roncero, I., Chowen, J. A., Maestre, O., de Heras, R. G., Muñoz, R. M., Eng, J., & Blázquez, E. (2000) · Metabolism · doi:10.1053/meta.2000.6251 · Cited by 158
Karasik, A., Aschner, P. J., Katzeff, H. L., Davies, M. J., & Stein, P. P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x261069 · Cited by 163
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Self-citationTherapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155
Self-citationGPR119 agonists for the treatment of type 2 diabetes
Jones, R. M., Leonard, J. N., Buzard, D. J., & Lehmann, J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903153878 · Cited by 164
Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes
Knudsen, L. B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030630m · Cited by 154
Wettergren, A., Wøjdemann, M., Meisner, S., Stadil, F., & Holst, J. J. (1997) · Gut · doi:10.1136/gut.40.5.597 · Cited by 153
Self-citationYoung, A. A., Gedulin, B. R., & RINK, T. J. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90192-4 · Cited by 150
Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., Wood, L., & Campbell, R. K. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.5.463 · Cited by 150
Hellström, P. M., Geliebter, A., Näslund, E., Schmidt, P. T., Yahav, E. K., Hashim, S. A., & Yeomans, M. R. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041142 · Cited by 149
Kaji, I., Karaki, S.-I., Tanaka, R., & Kuwahara, A. (2010) · Journal of Molecular Histology · doi:10.1007/s10735-010-9304-4 · Cited by 166
Hansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P. N., & Holst, J. J. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.6.e1010 · Cited by 148
Self-citationFrom the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
Self-citationThe physiological role of GLP-1 in human: incretin, ileal brake or more?
Schirra, J. R. J., & Göke, B. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.018 · Cited by 166
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Self-citationRecent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Liraglutide and obesity: a review of the data so far
Ladenheim, E. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 146
Hlebowicz, J., Hlebowicz, A., Lindstedt, S., Björgell, O., Höglund, P., Holst, J. J., Darwiche, G., & Almér, L. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26807 · Cited by 167
Self-citationSchirra, J., Houck, P., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2000) · Gut · doi:10.1136/gut.46.5.622 · Cited by 145
Deacon, C., Wamberg, S., Bie, P., Hughes, T., & Holst, J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 145
Self-citationNeumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 158
Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function
Perfetti, R., & Merkel, P. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430717 · Cited by 143
Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control
Lang Lehrskov, L., Lyngbaek, M. P., Soederlund, L., Legaard, G. E., Ehses, J. A., Heywood, S. E., Wewer Albrechtsen, N. J., Holst, J. J., Karstoft, K., Pedersen, B. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.008 · Cited by 135
Self-citationBarragán, J. M., Eng, J., Rodríguez, R., & Blázquez, E. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e784 · Cited by 142
Tolessa, T., Gutniak, M., Holst, J. J., Efendic, S., & Hellström, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci942 · Cited by 139
Self-citationVrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 153
Receptor‐mediated activation of gastric vagal afferents by glucagon‐like peptide‐1 in the rat
Bucinskaite, V., Tolessa, T., Pedersen, J., Rydqvist, B., Zerihun, L., Holst, J. J., & Hellström, P. M. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01317.x · Cited by 135
Self-citationWettergren, A., Petersen, H., ørskov, C., Christiansen, J., Sheikh, S. P., & Holst, J. J. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409092462 · Cited by 133
Self-citationRatliff, J. C., Leite, J. O. M., de Ogburn, R., Puglisi, M. J., VanHeest, J. L., & Fernández, M. L. (2010) · Nutrition Research · doi:10.1016/j.nutres.2010.01.002 · Cited by 150
Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat
Anini, Y., Fu–Cheng, X., Cuber, J. C., Kervran, A., Chariot, J., & Roz, C. (1999) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240050913 · Cited by 132
Holst, J. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00157-5 · Cited by 146
Self-citationUnraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives
Meier, J. J., Gallwitz, B., Schmidt, W. E., & Nauck, M. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01434-6 · Cited by 146
The Biology of Glucagon and the Consequences of Hyperglucagonemia
Wewer Albrechtsen, N. J., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 129
Self-citationChelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00870.2004 · Cited by 128
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“7), leaving behind an N-terminal fragment (proglucagon 1–30, also called glicentin-related pancreatic peptide, GRPP) as well as a large fragment corresponding to residues 72–158, the so-called major proglucagon fragment (MPGF) 5,8 .”
Self-citationAmato, A., Cinci, L., Rotondo, A., Serio, R., Faussone-pellegrini, M. S., Vannucchi, M. G., & Mulè, F. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01476.x · Cited by 124
Tolessa, T., Gutniak, M., Holst, J. J., Efendić, S., & Hellström, P. M. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026678925120 · Cited by 131
Self-citationGlucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes
Ahrén, B. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199808)20:8<642::aid-bies7>3.0.co;2-k · Cited by 125
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Dunning, B. E., Mangold, B. L., Mone, M. D., Russell, M. E., Weldon, S. C., & Hughes, T. E. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025522z · Cited by 121
D'Alessio, D. A., Vogel, R., Prigeon, R., Laschansky, E., Koerker, D., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 122
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationThe effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
Flint, A., Raben, A., Rehfeld, J. F., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 130
Self-citationThe Effect of Bariatric Surgery on Intestinal Absorption and Transit Time
Carswell, K. A., Vincent, R. P., Belgaumkar, A. P., Sherwood, R. A., Amiel, S. A., Patel, A. G., & le Roux, C. W. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1166-x · Cited by 130
Holst, J. J., & Deacon, C. F. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.005 · Cited by 129
Self-citationPeptide YY Is Secreted after Oral Glucose Administration in a Gender-Specific Manner
Kim, B.-J., Carlson, O. D., Jang, H.-J., Elahi, D., Berry, C., & Egan, J. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0409 · Cited by 118
Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety
Schmidt, P. T., Näslund, E. B., Grybäck, P., Jacobsson, H., Hartmann, B., Holst, J. J., & Hellström, P. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00175-7 · Cited by 116
Self-citationSwithers, S. E., Laboy, A. F., Clark, K., Cooper, S., & Davidson, T. L. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.024 · Cited by 113
Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu, H., Wiesenthal, S. R., MacDonald, P. E., McCall, R. H., Tchipashvili, V, Rashid, S., Satkunarajah, M., Irwin, D. M., Shi, Z. Q., Brubaker, P. L., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1045 · Cited by 113
Godinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Ali, S., Lamont, B. J., Charron, M. J., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43615 · Cited by 108
Parkes, D. G., Mace, K. F., & Trautmann, M. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 108
Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108
“Administration of exogenous GLP-1 has complex actions on gastric function (4, 22) and has even been suggested to be the major mechanism by which GLP-1 controls postprandial glucose (23).”
BackgroundTargeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Nagell, C. F., Wettergren, A., Pedersen, J. F., Mortensen, D., & Holst, J. J. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410004424 · Cited by 108
Self-citationNeural regulation of glucagon-like peptide-1 secretion in pigs
Hansen, L., Lampert, S., Mineo, H., & Holst, J. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00197.2004 · Cited by 107
Self-citationGlucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential
Gromada, J., Brock, B., Schmitz, O., & Rorsman, P. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.t01-1-pto950502.x · Cited by 105
Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104
Self-citationGlucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
Larsen, P. J., & Holst, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.026 · Cited by 125
Self-citationTreatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.155 · Cited by 103
Self-citationLópez de Maturana, R., Willshaw, A., Kuntzsch, A., Rudolph, R., & Donnelly, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212147200 · Cited by 103
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14944 · Cited by 102
Is glucagon-like peptide 1 an incretin hormone?
Nauck, M. A. (1999) · Diabetologia · doi:10.1007/s001250051165 · Cited by 112
Sørensen, L. B., Flint, A., Raben, A., Hartmann, B., Holst, J. J., & Astrup, A. V. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802247 · Cited by 107
Self-citationGLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide
Elahi, D., Egan, J. M., Shannon, R. P., Meneilly, G. S., Khatri, A., Habener, J. F., & Andersen, D. K. (2008) · Obesity · doi:10.1038/oby.2008.229 · Cited by 101
Qualmann, C., Nauck, M. A., Holst, J. J., �rskov, C., & Creutzfeldt, W. (1995) · Acta Diabetologica · doi:10.1007/bf00581038 · Cited by 111
Self-citationNovel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 112
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Thorkildsen, C., Neve, S., Larsen, B. D., Meier, E., & Petersen, J. S. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051987 · Cited by 104
The Utility of Exosomes in Diagnosis and Therapy of Diabetes Mellitus and Associated Complications
Sun, Y., Tao, Q., Wu, X., Zhang, L., Liu, Q., & Wang, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.756581 · Cited by 134
Post-prandial hyperglycemia. post-prandial hyperglycemia and diabetes.
Gin, H., & Rigalleau, V. (2000) · PubMed · Cited by 135
Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97
“Additionally, GLP-1 exerts multiple other effects, including inhibition of food intake [7], slowing gastric emptying [8], and inhibition of glucagon secretion [9].”
BackgroundGLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 95
Self-citationGLP-1/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis
Chen, J., Zhao, H., Ma, X., Zhang, Y., Lu, S., Wang, Y., Zong, C., Qin, D., Wang, Y., Yingfeng Yang, Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478872 · Cited by 94
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94
Raun, K., von Voss, P., & Knudsen, L. B. (2007) · Obesity · doi:10.1038/oby.2007.204 · Cited by 93
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Pei, Z., Li, X., von Geldern, T. W., Longenecker, K. L., Pireh, D., Stewart, K. D., Backes, B. J., Lai, C., Lubben, T. H., Ballaron, S. J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061436d · Cited by 93
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 88
Childhood Obesity: A Role for Gut Microbiota?
Sanchez, M., Panahi, S., & Tremblay, A. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120100162 · Cited by 85
Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1
Wishart, J. M., Horowitz, M., Morris, H. A., Jones, K. L., & Nauck, M. A. (1998) · Peptides · doi:10.1016/s0196-9781(98)00052-7 · Cited by 95
Kadowaki, T., & Kondo, K. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12092 · Cited by 86
McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84
“Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases.”
BackgroundFlock, G., Holland, D., Seino, Y., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2010-1047 · Cited by 84
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Deacon, C. (2008) · Frontiers in Bioscience · doi:10.2741/2799 · Cited by 80
Blase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004274432 · Cited by 82
Eto, T., Inoue, S., & Kadowaki, T. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01662.x · Cited by 82
Hussein, G. M. E., Matsuda, H., Nakamura, S., Hamao, M., Akiyama, T., Tamura, K., & Yoshikawa, M. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1849 · Cited by 82
Hansen, L., Hartmann, B., Mineo, H., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.021 · Cited by 93
Self-citationRyan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 81
Metadata
- Authors
- Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Digestive Diseases and Sciences
- Published
- 1993-04
- Volume
- 38
- Issue
- 4
- Pages
- 665-673
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2087063469
- Cited by
- 670
- References
- 39
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 20 · 2023: 9 · 2022: 14 · 2021: 22 · 2020: 10 · 2019: 19 · 2018: 17 · 2017: 18 · 2016: 23 · 2015: 27 · 2014: 25 · 2013: 21 · 2012: 25
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- gastric acid secretion, gastric emptying, postprandial insulin secretion, glucagon secretion, blood glucose, gastrin, incretins
- MeSH terms
- Adult, Depression, Chemical, Female, Gastric Acid, Gastric Emptying, Gastric Mucosa, Glucagon, Humans, Infusions, Intravenous, Lipase, Male, Pancreas, Peptide Fragments, Protein Precursors, Random Allocation, Reference Values, Time Factors, Trypsin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.